China-ready by design: Leveraging NMPA’s new 30‑working day IND pathway
China is becoming a global hub for oncology trials, offering access to a large and diverse patient population that can help speed recruitment, as well as expedited review pathways for INDs – but only sponsors who are ‘China ready’ will benefit.
